Ciba reportedly patented boldenone in 1949.  It subsequently developed several experimental esters of the drug in the 1950s and 1960s.  One of these was boldenone undecylenate, which was introduced for clinical use under the brand name Parenabol and saw some use in the late 1960s and early 1970s.  However, it was discontinued before the end of the 1970s.  Subsequently, boldenone undecylenate was introduced by Squibb under the brand name Equipose for veterinary use, most commonly in horses. 
Because of the military and non-military exploitation of nuclear fission , the Cold War brought forth some significant involuntary exposures to high-level radiation . The atomic bombings of Hiroshima and Nagasaki caused large-scale destruction through intense blast and fire, as well as acute and lingering radiation. Moreover, as a result of decades of nuclear-weapons production, experimentation, and testing, exposure to radiation above normal background levels occurred to scientists, technicians, military personnel, civilians, and animals. Several significant radiation-related accidents occurred at military and civilian nuclear reactors and facilities, causing direct fatalities, as well as involuntary occupational and public exposures.